Skip to main content
Ovarian Cancer
In Women with Platinum-Sensitive Ovarian Cancer, There Was No Difference in PFS Between Platinum-Based Chemotherapy and Olaparib plus Cediranib
Read More
Ovarian Cancer
Impact of Visible Residual Disease, Other Risk Factors on Advanced Ovarian Cancer Progression and Death: Real-World Evidence
Read More
Ovarian Cancer
Quality of Life Maintained with Niraparib in Newly Diagnosed Ovarian Cancer
Read More
Ovarian Cancer
Several Resources Offer Helpful Information on COVID-19 for Cancer Patients
Read More
Ovarian Cancer, PARP Inhibitors
PARP Inhibitors Consistently Improve PFS as First-Line Maintenance in Advanced Ovarian Cancer
Read More
Ovarian Cancer
Immunotherapy Triplet Has Significant Clinical Activity in Recurrent Ovarian Cancer
Read More
Ovarian Cancer
Online PARP Inhibitor Education Has Positive Impact on Oncologists’ and OB/GYNs’ Knowledge and Confidence
Read More
Biosimilars
Cost-Savings from Conversion from Reference Pegfilgrastim with On-Body Injector Device to Biosimilar Pegfilgrastim-jmdb in DLBCL
Read More
Biosimilars
Pharmacokinetic and Safety Equivalence Demonstrated Between HD204, a Biosimilar of Bevacizumab, in Healthy Male Subjects
Read More
Biosimilars
Utilization and Adherence Among Infliximab Biosimilar Initiators in a US National Commercial Insurance Database
Read More
Page 111 of 199
Results 1101 - 1110 of 1986